Free Trial

4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

$27.22
+1.43 (+5.54%)
(As of 07/12/2024 ET)

4D Molecular Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$45.63
67.62% Upside
High Forecast$81.00
Average Forecast$45.63
Low Forecast$24.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$45.63$45.63$44.22$36.25
Forecasted Upside67.62% Upside105.10% Upside93.05% Upside100.42% Upside
Get 4D Molecular Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

FDMT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FDMT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

4D Molecular Therapeutics Stock vs. The Competition

Type4D Molecular TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside67.62% Upside994.16% Upside9.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00+90.39%
6/7/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00+66.90%
4/15/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
4/1/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$70.00 ➝ $63.00+113.70%
4/1/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$30.00 ➝ $58.00+89.67%
2/7/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$81.00+143.90%
10/24/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$32.00+220.00%
10/18/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
10/18/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$24.00+145.90%
8/11/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$31.00+86.19%
6/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$28.00 ➝ $33.00+60.19%
4/13/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$14.00 ➝ $13.00-14.25%
11/14/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.00 ➝ $45.00+238.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:10 PM ET.

FDMT Forecast - Frequently Asked Questions

What is 4D Molecular Therapeutics' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for 4D Molecular Therapeutics is $45.63, with a high forecast of $81.00 and a low forecast of $24.00.

Should I buy or sell 4D Molecular Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FDMT shares.

Does 4D Molecular Therapeutics's stock price have much upside?

According to analysts, 4D Molecular Therapeutics's stock has a predicted upside of 111.89% based on their 12-month stock forecasts.

What analysts cover 4D Molecular Therapeutics?

4D Molecular Therapeutics has been rated by research analysts at Barclays, HC Wainwright, and Royal Bank of Canada in the past 90 days.

Do Wall Street analysts like 4D Molecular Therapeutics more than its competitors?

Analysts like 4D Molecular Therapeutics more than other "medical" companies. The consensus rating for 4D Molecular Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FDMT compares to other companies.


This page (NASDAQ:FDMT) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners